UnitedHealth stock price forecast: momentum fades as UNH consolidates below key resistance

Traders Union
All News
Financial News
UnitedHealth Group drops 0.63% today

Highlights

UnitedHealth is under U.S. Senate investigation for allegedly incentivizing nursing homes to reduce hospital transfers, raising scrutiny of its care practices.
UnitedHealth announced the planned sale of its UK Optum operation to TPG, continuing its portfolio streamlining strategy.
Several institutional investors reduced their holdings in UnitedHealth, and the company appointed former FDA Commissioner Dr. Scott Gottlieb to its board.

Senate probe and asset sale drive sentiment and portfolio moves

UnitedHealth has recently come under U.S. Senate scrutiny due to investigations alleging the company incentivized nursing homes to reduce hospital transfers. UnitedHealth also announced plans to sell its UK Optum operation to TPG, continuing its portfolio streamlining. Additionally, several institutional investors have reduced their holdings, and the company appointed Dr. Scott Gottlieb, a former FDA Commissioner, to its board.

Support holds amid momentum divergence and overbought signals

UNH shows clear technical strength above its short- and medium-term moving averages, with firm support at the Ichimoku Kijun level of $336.11 and immediate resistance near the MA-200 and $350. Momentum indicators are mixed: daily MACD remains positive, while low ADX signals a weak trend. Key oscillators indicate some overbought conditions, with RSI at 60.48, Stochastic RSI elevated at 78.80, and CCI in overbought territory. Bull/Bear Power favors buyers, supported by the Awesome Oscillator, but intraday price action reveals a mild downside move of 0.63% and a position near today's mid-range volatility, highlighting divergence between strong daily signals and slightly cooling intraday momentum.

Sideways movement likely as upside momentum stalls

Over the next five trading days, UNH is expected to trade within a typical volatility band between $339.89 and $346.74. With less than a 20% probability of a further immediate advance, the price is likely to consolidate sideways between $340 and $347. If momentum renews above $347, buyers could target $350; conversely, a drop below $340 may open a move toward $336 if selling pressure builds.

Anton Kharitonov, analyst at Traders Union, sees UnitedHealth holding firm above key short- and medium-term technical levels, but he remains cautious due to recent regulatory headlines and institutional selling. He notes that momentum is mixed, with strong daily indicators but weaker intraday signals and overstretched oscillators. The base case is a near-term sideways range between $340 and $347, with little sign of immediate upside. "With technicals showing hesitation and risks from government scrutiny, I stay defensive until buyers can push above $347 with conviction."

Previously it was reported that UnitedHealth Group is currently trading above short- and medium-term moving averages and immediate Ichimoku support, but remains below long-term resistance, indicating short-term strength but persistent longer-term headwinds. While MACD and overall buyer momentum support the upward trend, overbought oscillator readings and mixed momentum signals suggest caution and potential for near-term sideways movement within a narrow range.

Source of Data: UNH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.